Clinical efficacy and safety of siglitatin combined with metformin in treatment of type 2 diabetes mellitus with abdominal obesity
Chen Yun
He Yao
Ma Weiqing
Wang Guojuan
Abstract：Objective To explore the clinical efficacy and safety of siglitatin combined with metformin in treatment of type 2 diabetic patients with abdominal obesity.Methods From September 2015 to May 2017,102type 2 diabetic patients with abdominal obesity were enrolled in First People's Hospital of Hefei;4 patients were withdrawn from the test;98 patients were randomly divided into control group and observation group,with 49 cases in each group.The observation group took siglitatin combined with metformin and the control group took metformin for 12 weeks.Waist circumference,hip circumference,body mass index(BMI),fasting blood glucose(FBG),postprandial 2 h blood glucose(2 hPG),glycosylated hemoglobin(HbA1c),fasting insulin(HNS),insulin resistance index (HOMA-IR),systolic pressure (SBP),diastolic pressure (DBP),total cholesterol (TC),triacylglycerol (TG),high-density lipoprotein cholesterol (HDL-C),low-density lipoprotein cholesterol (LDL-C) and adverse reactions were analyzed.Results After treatment,waist circumference,hip circumference and BMI were significantly lower than those before treatment in both groups;BMI in observation group was significantly lower than that in control group[(21 ± 5) kg/m2 vs (24 ± 4) kg/m2] (P ＜ 0.05).After treatment,FBG and 2 hPG,HbA1c were significantly lower than those before treatment in both groups;FBG and 2 hPG in observation gToup were significantly lower than those in control group [(7.7 ± 1.0) mmol/L vs (9.2 ± 1.1) mmol/L,(9.7 ± 2.6) mmoL/L vs (12.2 ± 2.0) mmol/L] (P ＜ 0.05).After treatment,FINS was significantly higher and HOMA-IR,SBP,DBP were significantly lower than those before treatment in both groups;there were significant differences between observation group and control group(P ＜ 0.05).After treatment,TC,TG,LDL-C were significantly lower and HDL-C was significantly higher than those before treatment;there were also significant differences between observation group and control group(P ＜0.05).Incidence of hypoglycemia in observation group was significantly higher than that in control group[14.3％ (7/49) vs 4.1％ (2/49)] (P ＜0.05).Conclusion Siglitatin combined with metformin treating type 2 diabetic patients with abdominal obesity can effectively reduce blood glucose,improve insulin resistance,reduce blood pressure and regulate blood lipid;but the combined medication brings a high risk of hypoglycemia.
Keywords：Type 2 diabetes mellitusSiglitatinAbdominal obesity
Publication Date：2018-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 545-549 )